Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on July 10, 2023. The filing reports the election of a new member to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Adrienne L. Graves, Ph.D., as a Class I member of the Board of Directors, effective July 10, 2023. Dr. Graves brings significant experience in the pharmaceutical industry, having previously served as President and CEO of Santen Inc. and held board positions at Nicox S.A., Greenbrook TMS Inc., IVERIC bio, Inc., Oxurion NV, Akorn Inc., and TearLab Corporation.
Compensation and Governance Details
- Compensation: Dr. Graves will be compensated in accordance with the Company's non-employee director compensation policy.
- Equity Awards: Upon election, she received an option to purchase 72,000 shares of common stock at an exercise price of $5.04 per share (the closing price on the Effective Date) and a restricted stock unit award for 24,000 shares.
- Indemnification: Dr. Graves entered into the Company's standard Indemnification Agreement, which may require the Company to cover certain legal expenses and judgments arising from her service.
- Term: Her term will last until the 2024 annual meeting of stockholders.
Investor Verification Checklist
- Verify the current non-employee director compensation policy referenced in the May 1, 2023 proxy statement.
- Confirm the vesting schedule and terms for the 72,000 stock options and 24,000 restricted stock units granted to Dr. Graves.
- Review the standard Indemnification Agreement (Exhibit 10.12 to Form S-1) to understand potential financial liabilities.
- Monitor future filings for any changes to the Board composition or additional executive appointments.